Reference — Cardiac
Cardiac Biomarkers Reference
Quick-reference for cardiac biomarkers used in ACS and heart failure evaluation — normal values, rise time, peak time, duration of elevation, and clinical significance for each marker.
Educational use only. Reference ranges vary by institution and assay. Always use your facility’s established lab reference values and interpret in full clinical context. This material supports nursing education and exam review. It is not medical advice and is not a substitute for clinical judgment, institutional policy, or medical direction. Always follow facility protocols and current provider orders.
Cardiac Biomarker Comparison
| Biomarker | Normal Value | Rise Time | Peak Time | Duration Elevated | Clinical Significance |
|---|---|---|---|---|---|
| Troponin I (cTnI) | <0.04 ng/mL | 2–4 hrs | 12–24 hrs | 7–10 days | Gold standard for MI; cardiac-specific; elevated in NSTEMI and STEMI; serial draws required |
| High-sensitivity Troponin I (hsTnI) | Sex-specific; lab-defined | 1–2 hrs | 12–24 hrs | 7–10 days | Detects smaller MI earlier; enables 0/1-hr or 0/2-hr rule-out protocols |
| Troponin T (cTnT) | <0.01 ng/mL | 2–4 hrs | 12–48 hrs | 10–14 days | Cardiac-specific; slightly less specific than cTnI in renal failure (elevated more often); standard ACS marker |
| High-sensitivity Troponin T (hsTnT) | Sex-specific; lab-defined | 1–2 hrs | 12–24 hrs | 10–14 days | Rapidly changing standard of care; early rule-out at 0 and 2–3 hours with delta change |
| CK-MB | <5–10 ng/mL or <6% total CK | 3–6 hrs | 12–24 hrs | 2–3 days | Useful for detecting reinfarction (returns to baseline sooner); less specific than troponin (elevated in skeletal muscle injury) |
| BNP (B-type Natriuretic Peptide) | <100 pg/mL | Hours after wall stress | Variable | Days to weeks | Heart failure marker — indicates ventricular wall stress; NOT specific for MI; tracks treatment response in HF |
| NT-proBNP | <300 pg/mL rules out acute HF (age-adjusted rule-in: >450 for <50 yr, >900 for 50–75 yr, >1800 for >75 yr) | Hours after wall stress | Variable | Days to weeks (longer half-life than BNP) | More stable molecule than BNP; higher levels in renal failure; same clinical utility — HF severity/prognosis |
Serial Troponin Protocol
A single troponin result is insufficient to rule in or rule out MI. Trending is required.
| Draw Time | Standard Troponin Protocol | High-Sensitivity Protocol |
|---|---|---|
| 0 hr (presentation) | Draw at arrival | Draw at arrival |
| 1–2 hrs | Not routine | Second draw; delta assessed |
| 3 hrs | Second draw; delta assessed | Third draw if borderline |
| 6 hrs | Third draw; most sensitive window | May be sufficient with 0/2-hr protocol |
Non-ACS Causes of Troponin Elevation
| Cause | Mechanism |
|---|---|
| Acute PE with RV strain | Right ventricular pressure overload causes myocyte stretch and troponin release |
| Myocarditis | Inflammatory myocardial injury from viral, bacterial, or autoimmune causes |
| Sepsis / critical illness | Demand ischemia, microvascular dysfunction, direct myocardial depression |
| Renal failure (CKD/ESRD) | Reduced clearance + subclinical myocardial injury; chronically elevated in ESRD |
| Heart failure (acute decompensated) | Wall stress and demand ischemia cause low-level troponin release |
| Cardiac contusion / trauma | Direct mechanical myocardial injury |
| Tachyarrhythmias (SVT, AF with RVR) | Demand ischemia during sustained rapid rates |
| After cardioversion / defibrillation | Electrical energy causes transient myocardial injury |
NCLEX Pearls
- ›Troponin I and T are the gold standard for MI diagnosis — most sensitive and cardiac-specific.
- ›CK-MB returns to baseline in 2–3 days — the only biomarker useful for detecting reinfarction in that window.
- ›BNP and NT-proBNP measure heart failure severity (ventricular wall stress), not myocardial necrosis.
- ›A single normal troponin at presentation does not rule out NSTEMI — serial draws required.
- ›STEMI is diagnosed on ECG, not troponin — activate protocol immediately, not after labs return.
- ›Troponin can be elevated in non-ACS conditions (PE, sepsis, renal failure, myocarditis) — always interpret in clinical context.
Related Resources
Standards & sources
Fact-checked Jun 20, 2026This page is written to align with American Heart Association (AHA) · American College of Cardiology (ACC) · AHA ACLS Guidelines. It is an educational summary, not a citation of any single document — always verify specific doses, values, and protocols against current guidelines and your facility policy. How we source content →